1.
GV EXT Imperial Cancer Fund building and sign on wall.
0.11

2.
LV INT technicians at work (2 shots)
0.21

3.
SCU ZOOM in to CU Bottle of ICRF 159
0.28

4.
SCU Dr. Hellman speaks
1.30

5.
SV Technicians in laboratory.
1.33

6.
CU Diagram showing path of secondary tumours to the lungs of a mouse from the primary tumour.
1.36

7.
SV PAN from diagram to technicians working.
1.41

8.
CU Doctor SALSBURY SOF. Salisbury SOF continues over girl injecting mouse)
2.22

9.
CU Bottle of the new drug.
2.27


TRANSCRIPT:



DOCTOR HELLMAN: The drug was first synthesised in the laboratories of the Imperial Cancer Research Fund in 1966 by Doctor Crichton, and then it was shown in these laboratories, my laboratories here, that it had very marked anti-tumour activity in experimental animals. We were trying at the time to develop a method for testing drugs the effect of drugs on the spread of tumours. We have only been able to complete this technique, or to make it workable, in the last two years, and since then we have tried the effect of ICRF 159, and we have found to our great interest that it would completely inhibit the spread of secondary tumours while not interfering with the growth of the primary.



DOCTOR SALSBURY: Basically, we looked at the primary tumour, at the blood in which the malignant cells presumably passed and at the lungs where they established themselves in the untreated mice. And we found that in mice treated with ICRF 159 we could never find any cancer cells in the lungs or in the bloodstream. And this meant that the drug was in some way preventing cancer cells coming away from the primary growth.




Initials PBS/MR/CO/22.36 PBS/MR/CO/23.07



Script is copyright Reuters Limited. All rights reserved

Background: Research scientists working at the Imperial Cancer Research Fund in London have this week disclosed the development of a drug that has the quality of arresting cancer growth. The drug -- codenamed ICRF 159-was first synthesised in the ICRF laboratories four years ago, and has since been used in animal and human trials.

The scientists who have been working on the development of the drug describe it as significant. ICRF 159 has been shown to prevent the development of secondary cancer growths, one of the characteristics of the disease that makes cure difficult. The researchers have emphasised that tests to date have been concentrated on preventing secondary tumours. It will take some time to complete the animal and human clinical tests and evaluate the results.

The Imperial Cancer Research Fund is one of the major cancer research centres of the world, and in the past few years has made a number of major contributions in expanding international understanding of the possible causes of cancer, and possible counter-agents.

Two scientists at the ICRF headquarters in London gave details of the development and operation of ICRF 159.: